A technical help webinar was held for potential candidates of the next Discover of Funding Alternative (NOFO): Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required) . Nationwide Institute of Psychological Well being workers answered questions associated to this NOFO.
The aim of this NOFO is to assist one medical trial community to guage organic, digital, cognitive, and medical end result measures in people at medical excessive danger (CHR) for psychosis in Proof of Precept (PoP) trial(s) utilizing a pharmacological intervention. Distinctive drug improvement instruments developed by means of AMP® SCZ initiative will probably be evaluated within the PoP trial(s). The compound(s) chosen for testing by the AMP SCZ Steering Committee will have an effect on a pathophysiologically related mechanism and have the potential to supply a detectable sign on organic, digital, cognitive, or medical end result measures inside a 12-16 week interval of research.
Learn the transcript.
Division of Translational Analysis
Jonathan Sabbagh, Ph.D.